You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Alemtuzumab in Chronic Lymphocytic Leukemia

Version: 2 ID: 6-16 Version 2 fév 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
G. Fraser, C.A. Smith, K. Imrie, R. Meyer , Hematology Disease Site Group

Patient Population

Adult patients with CLL.

Research Question(s)

  1. Is alemtuzumab a beneficial treatment option, with respect to outcomes such as survival, response rate, response duration, time-to-progression, and quality of life, for patients with Bcell chronic lymphocytic leukemia (CLL)?
  2. What toxicities are associated with the use of alemtuzumab?
  3. Which patients are more likely, or less likely, to benefit from treatment with alemtuzumab?
pdf download Full Report (PDF) (1.27 Mo)